Genetic Determinants of ACEI Prodrug Activation
| Status: | Recruiting |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 5/6/2018 |
| Start Date: | April 1, 2017 |
| End Date: | January 2021 |
| Contact: | Haojie Zhu, PhD |
| Email: | hjzhu@med.umich.edu |
| Phone: | 7347638449 |
Angiotensin-converting enzyme inhibitors (ACEIs) are among the most frequently prescribed
medications worldwide for the treatment of essential hypertension, left ventricular systolic
dysfunction, acute myocardial infarction, and prevention of the progression of diabetic
nephropathy. However, the outcome of ACEI treatment varies significantly between individuals
and selected populations. Suboptimal response, therapeutic failure, and significant side
effects are commonly documented in patients receiving ACEI therapy. Approximately 80% of the
ACEIs available for use in the US are synthesized as esterified prodrugs in order to improve
otherwise poor oral bioavailability of the active molecule. The activation of ACEI prodrugs
primarily occurs in the liver via metabolic de-esterification of the parent drug. The
critical activation step is essential in delivering a successful therapeutic outcome since
the active metabolites are approximately 10-1000 times more potent relative to their
respective parent compounds. Carboxylesterase 1 (CES1), the most abundant hydrolase in the
liver, is responsible for the activation of ACEI prodrugs in humans. Marked interindividual
variability in CES1 expression and activity has been documented, which results in varied
therapeutic efficacy and tolerability of many drugs serving as substrates of CES1. Genetic
variation of CES1 is considered to be a major factor contributing to variability in CES1
function. The study team proposes to conduct a multiple-dose healthy volunteer study to
evaluate the impact of CES1 genetic variation on the activation, pharmacokinetics, and
pharmacodynamics of enalapril, a model ACEI prodrug activated by CES1. The completion of this
study will represent a major step towards the establishment of an evidence base from which a
more individualized use of ACEI prodrugs can emerge.
medications worldwide for the treatment of essential hypertension, left ventricular systolic
dysfunction, acute myocardial infarction, and prevention of the progression of diabetic
nephropathy. However, the outcome of ACEI treatment varies significantly between individuals
and selected populations. Suboptimal response, therapeutic failure, and significant side
effects are commonly documented in patients receiving ACEI therapy. Approximately 80% of the
ACEIs available for use in the US are synthesized as esterified prodrugs in order to improve
otherwise poor oral bioavailability of the active molecule. The activation of ACEI prodrugs
primarily occurs in the liver via metabolic de-esterification of the parent drug. The
critical activation step is essential in delivering a successful therapeutic outcome since
the active metabolites are approximately 10-1000 times more potent relative to their
respective parent compounds. Carboxylesterase 1 (CES1), the most abundant hydrolase in the
liver, is responsible for the activation of ACEI prodrugs in humans. Marked interindividual
variability in CES1 expression and activity has been documented, which results in varied
therapeutic efficacy and tolerability of many drugs serving as substrates of CES1. Genetic
variation of CES1 is considered to be a major factor contributing to variability in CES1
function. The study team proposes to conduct a multiple-dose healthy volunteer study to
evaluate the impact of CES1 genetic variation on the activation, pharmacokinetics, and
pharmacodynamics of enalapril, a model ACEI prodrug activated by CES1. The completion of this
study will represent a major step towards the establishment of an evidence base from which a
more individualized use of ACEI prodrugs can emerge.
Inclusion Criteria:
- Subjects must be male and female (50:50) between the ages of 18-55 years
- Females must have a negative urine pregnancy test prior to the study
- All subjects must have no clinically significant diseases or clinically significant
abnormal laboratory values as assessed during the screening medical history, nursing
assessment, and laboratory evaluations
- Informed consent must be signed by the eligible subject prior to the initiation of any
study procedures
Exclusion Criteria:
- The presence of a known medical condition that would preclude the use of enalapril
- The presence of any surgical or medical condition (active or chronic) that may
interfere with drug absorption, distribution, metabolism, or excretion.
- A positive urine pregnancy test in the MCRU prior to the study
- No subjects weighing under 50 kg will be selected
- The lack of use of acceptable methods of birth control unless abstinent
- Subjects who regularly take medications, vitamins, herbal supplements
- The use of any illicit drugs or habitual consumption of large quantities of ethanol
(>3 drinks/day)
- The consumption of grapefruit or grapefruit juice a week prior to, and during the
study
- Asians will not be included in the study as the CES1 SNP G143E is absent in this
population
- Subjects hypersensitive to enalapril
- Subject with a history of angioedema
- Smokers
We found this trial at
1
site
University of Michigan The University of Michigan was founded in 1817 as one of the...
Click here to add this to my saved trials
